NanoString nCounter® Approach in Breast Cancer: A Comparative Analysis with Quantitative Real-Time Polymerase Chain Reaction, In Situ Hybridization, and Immunohistochemistry.
10.4048/jbc.2017.20.3.286
- Author:
Jiyeon HYEON
1
;
Soo Youn CHO
;
Min Eui HONG
;
So Young KANG
;
Ingu DO
;
Young Hyuck IM
;
Eun Yoon CHO
Author Information
1. Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. eunyoon.cho@samsung.com
- Publication Type:Original Article
- Keywords:
Breast neoplasms;
ErbB-2;
Gene expression;
Immunohistochemistry;
In situ hybridization
- MeSH:
Breast Neoplasms*;
Breast*;
Estrogens;
Gene Amplification;
Gene Expression;
Humans;
Immunohistochemistry*;
In Situ Hybridization*;
Korea;
Polymerase Chain Reaction;
Real-Time Polymerase Chain Reaction*;
Receptor, Epidermal Growth Factor;
Receptors, Progesterone;
Reverse Transcription;
RNA, Messenger;
Tertiary Care Centers
- From:Journal of Breast Cancer
2017;20(3):286-296
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Accurate testing for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) is essential for breast cancer treatment. At present, immunohistochemistry (IHC)/florescence in situ hybridization (FISH) are widely accepted as the standard testing methods. To investigate the value of NanoString nCounter®, we performed its comparative analysis with IHC/FISH and real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) for the assessment of ER, PR, and HER2. METHODS: Data on IHC/FISH results for ER, PR, and HER2 in 240 patients from a single tertiary hospital in Korea were collected and compared with NanoString nCounter® and qRT-PCR results at a single institution. RESULTS: Expression levels for each gene using NanoString nCounter® showed good correlation with the corresponding data for protein expression by IHC (p<0.001) and gene amplification status for HER2 (p<0.001). Comparisons between gene expression and IHC data showed good overall agreement with a high area under the curve (AUC) for ESR1/ER (AUC=0.939), PgR/PR (AUC=0.796), and HER2/HER2 (AUC=0.989) (p<0.001). CONCLUSION: The quantification of ER, PgR, and HER2 mRNA expression with NanoString nCounter® may be a viable alternative to conventional IHC/FISH methods.